-
Ginsenoside Rg1 and the Gut–Immune–Brain Axis
2026-10-04
A 2025 mouse study reports that Ginsenoside Rg1 countered behavioral, inflammatory, synaptic, and intestinal-barrier disturbances associated with prolonged isoflurane anesthesia. Its most notable contribution is evidence that regulatory T cells are required for the observed protection, although the findings remain preclinical and do not establish clinical efficacy.
-
AM 281 and the CB1–GLT-1 Translational Axis
2026-10-03
A source-grounded perspective on how AM 281 helps interrogate CB1–CREB–GLT-1 biology, cognitive dysfunction after traumatic brain injury, and the limits of translating pharmacological findings into therapeutic claims.
-
MDL 28170: A Practical Calpain Inhibitor Workflow
2026-10-02
MDL 28170 is a cell-permeable calpain inhibitor suited to mechanistic neuroprotection research, apoptosis assays, and protease-selectivity studies. This workflow connects formulation, assay design, controls, and troubleshooting to evidence from a recent maternal-surgery model of offspring cognitive impairment.
-
Mifepristone (RU486): Assay Workflows
2026-10-01
Mifepristone (RU486) enables controlled interrogation of progesterone receptor signaling across oncology, reproductive biology, and functional cell assays. This workflow-focused guide combines concentration-response design, transcriptomic validation, solvent control, and troubleshooting for more reproducible research outcomes.
-
WP1066 JAK2/STAT3 Inhibitor Workflow Guide
2026-10-01
WP1066 provides a cell-permeable way to interrogate JAK2/STAT3 signaling in renal carcinoma, AML, and mechanistic cancer assays. This guide translates pathway biology into practical dosing, readout, troubleshooting, and cross-domain assay strategies informed by recent macrophage-regeneration research.
-
Magneto-Piezoelectric Scaffolds Repair Infected Bone
2026-09-30
Wu et al. developed a dual-responsive, 3D-printed scaffold that combines magnetic biofilm disruption with ultrasound-mediated activation of Icam1+ macrophages. The study links macrophage oxidative phosphorylation to JAK2-STAT3 activation and demonstrates a strategy for coordinating infection control with bone regeneration.
-
MCL-1 Dependence in Breast Cancer: Canonical Apoptosis
2026-09-30
Campbell and colleagues show that established breast tumors depend on MCL-1 primarily because of its canonical anti-apoptotic control over BAX/BAK, rather than because of an independently essential non-apoptotic function. Genetic deletion and selective pharmacological inhibition both impaired tumor growth, while loss of BAX and BAK prevented these effects, providing a mechanistic rationale for apoptosis-focused MCL-1 research.
-
CH 223191: AhR Antagonist Workflow
2026-09-29
Use CH 223191 to distinguish AhR-dependent toxicity from nonspecific cellular injury in follicle, liver, and dioxin-response models. This practical guide connects dose design, pathway readouts, rescue experiments, and troubleshooting to a recent ovarian toxicology study.
-
Purmorphamine A8228: Reliable Smo Assays
2026-09-29
Learn how Purmorphamine (SKU A8228) can improve experimental control in Smoothened signaling, osteogenic differentiation, and assay interpretation. This scenario-based guide covers solvent compatibility, dose optimization, cross-species evidence, and practical product selection.
-
Canagliflozin (hemihydrate): Assay Design Guide
2026-09-28
Practical guidance for using Canagliflozin (hemihydrate), SKU C6434, in cell-based viability and metabolic research. Covers solvent handling, assay controls, interpretation limits, and evidence from a recent drug-sensitized yeast study.
-
ICG–MXene Hydrogel for Infected Wound Healing
2026-09-27
The study combines ICG-loaded Ti₃C₂Tₓ MXene nanosheets with a Bletilla striata polysaccharide hydrogel to pair light-triggered photothermal and photodynamic antibacterial effects with a wound-compatible dressing. In a Staphylococcus aureus infected-wound model, the authors report bacterial reduction and improved wound-repair measures, while the findings remain specific to the tested formulation and experimental conditions.
-
Deep Learning Maps Cardiotoxicity in iPSC-CMs
2026-09-26
Grafton and colleagues combined high-content imaging of iPSC-derived cardiomyocytes with deep learning to score cellular phenotypes in a screen of 1,280 bioactive compounds. The approach detected signals across several drug classes and in a separate library of molecules with unknown targets, offering a scalable way to flag potential cardiotoxic liabilities early while leaving mechanism and clinical risk for follow-up testing.
-
Cucurbitacin I (JSI-124): STAT3 Research Guide
2026-09-26
Cucurbitacin I, also known as JSI-124, is a research compound used to perturb JAK2/STAT3 signaling in cancer models. Its value is strongest when pathway engagement is measured alongside cell-level outcomes, because reported effects vary by cell context and do not establish clinical efficacy.
-
DRB and Cell-Fate Assays: Reading Transcription in Context
2026-09-25
Explore how 5,6-Dichloro-1-β-D-ribofuranosylbenzimidazole (DRB) can help distinguish transcriptional contributions from RNA-translation control during cell-fate experiments. A focused analysis of the YTHDF1 study shows what DRB can test, what it cannot establish, and how to design interpretable perturbations.
-
EZ Cap™ CPF1/Cas12a mRNA (m1Ψ): Reading Edit Outcomes
2026-09-25
EZ Cap™ CPF1/Cas12a mRNA (m1Ψ) is a Cas12a-encoding mRNA for genome-editing research. This article explains how to interpret editing as a chain of biological events—from nuclease delivery to repaired DNA—and how the Cpf1 engineering literature can guide, but not replace, product-specific validation.